Broken String Biosciences
Broken String’s platform overcomes the limitation of ‘off-target’ edits (i.e., unintended changes) that can occur in the genome during the editing process with renowned gene editing tools such as the pioneering CRISPR-Cas9 platform.
The INDUCE-seq™ technology novelly allows drug developers to evaluate any changes and assess a gene-editing tool’s specificity. Crucially, the process facilitates novel therapeutic development by allowing the developer to unlock new targets within the genome.
In 2024, Broken String announced a research collaboration with the world-leading Francis Crick Institute to uncover the biology of health and disease. The project will leverage INDUCE-seq™ and exceed its current capabilities to develop new and original applications for its technology.
The collaboration will see Broken String investigate the role genomic instability plays in the development of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Backed by Illumina and Tencent and based at the Wellcome Genome Campus in Cambridge, the company is expanding on both sides of the Atlantic.
